BLASINGLE-USEVIALPriority Review
Approved
Feb 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
12
Data completeness
5/8 — Partial
Priority Review
ARCALYST (rilonacept) by Kiniksa Pharmaceuticals is interleukin-1 alpha (il-1α) and interleukin-1 beta (il-1β) cytokine trap. First approved in 2008.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARCALYST (rilonacept) is a fusion protein that acts as a soluble decoy receptor for interleukin-1 alpha and beta (IL-1α/β), blocking IL-1 signaling at the source. It is indicated for rare autoinflammatory disorders including CAPS (Cryopyrin-Associated Periodic Syndromes) and DIRA (Deficiency of Interleukin-1 Receptor Antagonist), conditions driven by uncontrolled IL-1 production. By trapping IL-1 cytokines before they engage cell-surface receptors, rilonacept halts the inflammatory cascade characteristic of these genetic disorders.
$25MPart D
LOE ApproachingARCALYST operates in a niche rare disease space with modest Part D spending ($25M) and approximately 1,000 annual claims, indicating a small but stable patient population with limited commercial expansion opportunity.
Mechanism of Action
interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) cytokine trap. Rilonacept blocks IL-1 signaling by acting as a soluble decoy receptor that binds both IL-1α and IL-1β and prevents its interaction with cell surface receptors. Rilonacept also binds interleukin-1 receptor antagonist…
Indications
Worked on ARCALYST at Kiniksa Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.